USD
+$0.00
(+0.00%
)At Close (As of Sep 5, 2025)
$263.74M
Market Cap
-
P/E Ratio
-9.74
EPS
$98.00
52 Week High
$10.29
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $2.3M |
Total Revenue | $2.3M |
Cost Of Revenue | $3.6M |
Costof Goods And Services Sold | $3.6M |
Operating Income | -$92M |
Selling General And Administrative | $31M |
Research And Development | $64M |
Operating Expenses | $94M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.6M |
Income Before Tax | -$83M |
Income Tax Expense | $141K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$84M |
Comprehensive Income Net Of Tax | - |
Ebit | -$92M |
Ebitda | -$88M |
Net Income | -$84M |
Field | Value (USD) |
---|---|
Total Assets | $226M |
Total Current Assets | $132M |
Cash And Cash Equivalents At Carrying Value | $56M |
Cash And Short Term Investments | $56M |
Inventory | - |
Current Net Receivables | $1.7M |
Total Non Current Assets | $95M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $37M |
Short Term Investments | $70M |
Other Current Assets | $3.7M |
Other Non Current Assets | - |
Total Liabilities | $66M |
Total Current Liabilities | $15M |
Current Accounts Payable | $4M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.6M |
Total Non Current Liabilities | $51M |
Capital Lease Obligations | $45M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $45M |
Other Current Liabilities | $4.9M |
Other Non Current Liabilities | $1.5M |
Total Shareholder Equity | $160M |
Treasury Stock | - |
Retained Earnings | -$267M |
Common Stock | $9K |
Common Stock Shares Outstanding | $8.9M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$60M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.6M |
Capital Expenditures | $18M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$123M |
Cashflow From Financing | $69M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$84M |
Field | Value (USD) |
---|---|
Gross Profit | $2.3M |
Total Revenue | $2.3M |
Cost Of Revenue | $3.6M |
Costof Goods And Services Sold | $3.6M |
Operating Income | -$92M |
Selling General And Administrative | $31M |
Research And Development | $64M |
Operating Expenses | $94M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.6M |
Income Before Tax | -$83M |
Income Tax Expense | $141K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$84M |
Comprehensive Income Net Of Tax | - |
Ebit | -$92M |
Ebitda | -$88M |
Net Income | -$84M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.